CAS: 1809068-70-9
Marca | Dados do produto | Pureza | Gama de preços | Estimativa de entrega |
---|---|---|---|---|
N-[(1S,2S,3R)-3-(5,6-Dihydrobenzo[b][1]benzazepin-11-yl)-2-hydroxycyclohexyl]-4-(trifluoromethoxy)benzenesulfonamide REF: 3D-JXC06870CAS: 1809068-70-9 | Min. 95% | 453,00 €~4.405,00 € | Qui 23 Jan 25 | |
SMAP-2 REF: TM-T12934CAS: 1809068-70-9 | 98% | A consultar | Qui 30 Jan 25 |
N-[(1S,2S,3R)-3-(5,6-Dihydrobenzo[b][1]benzazepin-11-yl)-2-hydroxycyclohexyl]-4-(trifluoromethoxy)benzenesulfonamide
CAS:1809068-70-9
Please enquire for more information about N-[(1S,2S,3R)-3-(5,6-Dihydrobenzo[b][1]benzazepin-11-yl)-2-hydroxycyclohexyl]-4-(trifluoromethoxy)benzenesulfonamide including the price, delivery time and more detailed …
Fórmula:
C27H27F3N2O4S
Pureza:
Min. 95%
Peso molecular:
532.6 g/mol
Ref: 3D-JXC06870
1mg | 453,00 € | ||
2mg | 711,00 € | ||
5mg | 1.276,00 € | ||
10mg | 1.855,00 € | ||
25mg | 4.405,00 € |
Entrega estimada em Estados Unidos, Quinta-feira 23 de Janeiro de 2025
SMAP-2
CAS:1809068-70-9
SMAP-2: oral PP2A activator, targets Aα subunit, halts KRAS-mutant lung cancer growth.
Fórmula:
C27H27F3N2O4S
Pureza:
98%
Cor e Forma:
Solid
Peso molecular:
532.57
Ref: TM-T12934
25mg | 1.410,00 € | ||
50mg | 1.845,00 € | ||
100mg | 2.329,00 € |
Entrega estimada em Estados Unidos, Quinta-feira 30 de Janeiro de 2025